Orient Europharma Co Ltd (4120) - Total Assets
Based on the latest financial reports, Orient Europharma Co Ltd (4120) holds total assets worth NT$12.43 Billion TWD (≈ $391.55 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Orient Europharma Co Ltd for net asset value and shareholders' equity analysis.
Orient Europharma Co Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Orient Europharma Co Ltd's total assets have evolved over time, based on quarterly financial data.
Orient Europharma Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Orient Europharma Co Ltd's total assets of NT$12.43 Billion consist of 34.4% current assets and 65.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 12.4% |
| Accounts Receivable | NT$774.69 Million | 6.7% |
| Inventory | NT$1.03 Billion | 8.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Orient Europharma Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Orient Europharma Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orient Europharma Co Ltd's current assets represent 34.4% of total assets in 2024, a decrease from 53.3% in 2015.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2024, down from 19.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 8.9% of total assets.
Orient Europharma Co Ltd Competitors by Total Assets
Key competitors of Orient Europharma Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Orient Europharma Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.65 | 0.98 | 1.78 |
| Quick Ratio | 1.22 | 0.71 | 1.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.74 Billion | NT$-61.59 Million | NT$1.89 Billion |
Orient Europharma Co Ltd - Advanced Valuation Insights
This section examines the relationship between Orient Europharma Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.70 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 7.0% |
| Total Assets | NT$11.57 Billion |
| Market Capitalization | $14.07K USD |
Valuation Analysis
Below Book Valuation: The market values Orient Europharma Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Orient Europharma Co Ltd's assets grew by 7.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Orient Europharma Co Ltd (2015–2024)
The table below shows the annual total assets of Orient Europharma Co Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$11.57 Billion ≈ $364.53 Million |
+7.02% |
| 2023-12-31 | NT$10.81 Billion ≈ $340.63 Million |
+3.66% |
| 2022-12-31 | NT$10.43 Billion ≈ $328.61 Million |
+10.92% |
| 2021-12-31 | NT$9.40 Billion ≈ $296.26 Million |
+15.24% |
| 2020-12-31 | NT$8.16 Billion ≈ $257.07 Million |
+3.64% |
| 2019-12-31 | NT$7.87 Billion ≈ $248.03 Million |
+8.74% |
| 2018-12-31 | NT$7.24 Billion ≈ $228.09 Million |
+8.81% |
| 2017-12-31 | NT$6.65 Billion ≈ $209.63 Million |
+2.58% |
| 2016-12-31 | NT$6.49 Billion ≈ $204.35 Million |
+18.48% |
| 2015-12-31 | NT$5.47 Billion ≈ $172.47 Million |
-- |
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more